Kazia to present on Cantrixil at American Association for Canc...
SYDNEY, March 25, 2019 /PRNewswire-AsiaNet/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual ...
Authors: LATEST ASIANET NEWS RELEASES